Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC

Phase 1WithdrawnNCT02059967

Virginia Commonwealth University

Overview

This phase I trial studies the side effects and best dose of image-guided adaptive radiation therapy using active breathing control when given together with chemotherapy and simultaneous integrated boost in treating patients with stage IIA-IIIB non-small cell lung cancer that cannot be removed by surgery. Image-guided adaptive radiation therapy aims radiation therapy right at the tumor so that higher radiation doses can be given without causing bad side effects. Giving these higher doses may help control the tumor better. Breathing causes organs and tissues, including the tumor, to move within the chest. Active breathing control may reduce the volume that needs to be treated. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving image-guided adaptive radiation therapy using active breathing control with chemotherapy and simultaneous integrated boost may be an effective treatment for non-small cell lung cancer.

OUTLINE: This is a dose-escalation study of IGART. Patients undergo IGART using active breathing control (ABC) 5 days a week for 7 weeks, for a total of 33 fractions with simultaneous integrated volume adapted boost (SIVAB) during fractions 26-33. Patients also receive paclitaxel intravenously (IV) over 1 hour and carboplatin IV over 30 minutes once a week for 6 weeks. After completion of study treatment, patients are followed up periodically for 5 years.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Adenocarcinoma of the Lung

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically-proven (by biopsy or cytology), unresectable or inoperable lung cancer of the following histologic types: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, non-small cell carcinoma not otherwise specified. * The tumor stage must be Stage IIA-IIIB (AJCC 7th edition). See http://aboutcancer.com/AJCC 7th lung 1.gif and http://aboutcancer.com/AJCC 7th lung 2.gif for staging. * All detectable tumor must be encompassed by radiation therapy fields. * 18-fluorodeoxyglucose PET is required for staging and treatment planning. * Atelectasis, if present, must involve less than a complete lung. * Laboratory values: * Neutrophils \>1500/µL * Platelets \>100,000/µL * Bilirubin \< 1.5 mg/dL * Aspartate aminotransferase (AST; formerly serum glutamic oxaloacetic transaminase \[SGOT\]) \< 2x upper limit normal * Alanine aminotransferase (ALT; formerly serum glutamic pyruvic transaminase \[SGPT\]) \< 2x upper limit normal * Serum creatinine \< 2.0 mg/dL * Glomerular filtration rate (GFR) calculated (kidney function test) within 30 days must be ≥ 59 mL/min * Pulmonary function test (PFT) with FEV-1 ≥ 1.0 L/sec * Plan of curative radiotherapy with or without concurrent chemotherapy. * Karnofsky Performance Scale score of ≥ 70%. * Age ≥ 18 years old. * Measurable disease on the planning CT. * Patient must have a completed IMRT plan to 66 Gy in 2 Gy fractions with ≥ 95% of the PTV covered by the prescription dose, and the attending physician must have reviewed and approved the DVHs as follows: * total lung V20 Gy ≤ 30% * mean esophageal dose ≤ 34 Gy * esophageal planning organs-at-risk volume (PRV) V60 Gy ≤ 30% * heart V40 Gy ≤ 50% * maximum brachial plexus dose ≤ 66 Gy * maximum spinal cord PRV dose ≤ 50 Gy * maximum aorta dose ≤ 66 Gy * maximum main bronchus dose ≤ 66 Gy * maximum dose ≥ 66 Gy allowed in only one lobar bronchus. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Complete tumor resection, recurrent disease, or those patients eligible for definitive surgery. * Prior radiation therapy to the thorax. * Previous chemotherapy or previous biologic response modifiers for current lung cancer or within the past 5 years. * Clinically significant pleural effusions, pericardial effusions, or superior vena cava syndrome. * Oxygen supplementation required during therapy. * Involvement of the brachial plexus, or infiltration of the aorta, heart, or esophagus. * Tumors that affect more than one lobar bronchus, except the second involved bronchus in the right middle lobe bronchus. * Unable to perform the BH procedures, unless tumor motion is ≤ 3 mm. * Myocardial infarction within the last 6 months, symptomatic heart disease, uncompensated chronic obstructive pulmonary disease (COPD), or uncontrolled bronchospasms. * History of a prior malignancy from which the patient has not been disease free for a minimum of 2 years, other than adequately treated basal/squamous skin cancer or in situ cervix cancer or other in situ malignancy. * Pregnant or lactating women.

Outcomes

Primary Outcomes

MTD, defined as the highest dose level at which =< 3 out of 7 patients experience a dose-limiting toxicity

(using daily image-guidance, deformable image registration, adaptive replanning at defined time points, and dose intensification at normal tissue tolerance) of radiotherapy delivered concomitantly with standard chemotherapy.

Time frame: 3 months

Secondary Outcomes

Incidence of acute toxicity measured using the National Cancer Institution Common Terminology for Adverse Events version 4.0

Toxicities associated with higher dose per fraction during the SIVAB phase of the protocol will be tabulated and analyzed with respect to treatment dose, respective normal tissue structure and dose-volume parameters.

Time frame: Up to 90 days from radiation therapy start

Incidence of late toxicity measured using the Radiation Therapy Oncology Group Late Radiation Morbidity Scoring

Time frame: Up to 5 years

Practicability of the approach

Variations in respiratory patterns, tumor and CTV positions, as well as tumor volumes will be assessed on the respective under-treatment imaging studies. The feasibility of deformable image registration will be benchmarked against manual contours of targets and normal tissue. The practicability of IGART will be measured by assessing the necessary time, IT and personnel resources needed to conduct the study.